Multivesicular Liposome (Depofoam) in Human Diseases.
Bahare Salehi, Abhay Prakash Mishra, Manisha Nigam, Farzad Kobarfard, Zeeshan Javed, Sadegh Rajabi, Khushbukhat Khan, Hafiz Ahsan Ashfaq, Toqeer Ahmad, Raffaele Pezzani, Karina Ramírez‐Alarcón, Miquel Martorell, William C. Cho, Seyed Abdulmajid Ayatollahi, Javad Sharifi‐Rad
Abstract
Drug development is a key point in the research of new therapeutic treatments for increasing maximum drug loading and prolonged drug effect. Encapsulation of drugs into multivesicular liposomes (DepoFoam) is a nanotechnology that allow delivery of the active constituent at a sufficient concentration during the entire treatment period. This guarantees the reduction of drug administration frequency, a very important factor in a prolonged treatment. Currently, diverse DepoFoam drugs are approved for clinical use against neurological diseases and for post-surgical pain management while other are under development for reducing surgical bleeding and for post-surgical analgesia. Also, on pre-clinical trials on cancer DepoFoam can improve bioavailability and stability of the drug molecules minimizing side effects by site-specific targeted delivery. In the current work, available literature on structure, preparation and pharmacokinetics of DepoFoam are reviewed. Moreover, we investigated approved DepoFoam formulations and preclinical studies with this nanotechnology.